JP7591504B2 - Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 - Google Patents
Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 Download PDFInfo
- Publication number
- JP7591504B2 JP7591504B2 JP2021542104A JP2021542104A JP7591504B2 JP 7591504 B2 JP7591504 B2 JP 7591504B2 JP 2021542104 A JP2021542104 A JP 2021542104A JP 2021542104 A JP2021542104 A JP 2021542104A JP 7591504 B2 JP7591504 B2 JP 7591504B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hpmcas
- solid dispersion
- amorphous solid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Dispersion Chemistry (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024200421A JP2025017374A (ja) | 2019-01-25 | 2024-11-18 | Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019073254 | 2019-01-25 | ||
| CNPCT/CN2019/073254 | 2019-01-25 | ||
| CN2019095227 | 2019-07-09 | ||
| CNPCT/CN2019/095227 | 2019-07-09 | ||
| PCT/CN2020/073944 WO2020151756A1 (en) | 2019-01-25 | 2020-01-23 | Stable solid dispersions of b-raf kinase dimer inhibitor, methods of preparation, and uses therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024200421A Division JP2025017374A (ja) | 2019-01-25 | 2024-11-18 | Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022517675A JP2022517675A (ja) | 2022-03-09 |
| JPWO2020151756A5 JPWO2020151756A5 (https=) | 2023-01-27 |
| JP2022517675A5 JP2022517675A5 (https=) | 2023-01-27 |
| JP7591504B2 true JP7591504B2 (ja) | 2024-11-28 |
Family
ID=71735582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542104A Active JP7591504B2 (ja) | 2019-01-25 | 2020-01-23 | Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 |
| JP2024200421A Pending JP2025017374A (ja) | 2019-01-25 | 2024-11-18 | Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024200421A Pending JP2025017374A (ja) | 2019-01-25 | 2024-11-18 | Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12582604B2 (https=) |
| EP (1) | EP3914591A4 (https=) |
| JP (2) | JP7591504B2 (https=) |
| KR (1) | KR20210120039A (https=) |
| CN (1) | CN113330011A (https=) |
| AU (1) | AU2020211000B2 (https=) |
| BR (1) | BR112021014563A2 (https=) |
| CA (1) | CA3123476A1 (https=) |
| IL (1) | IL284636A (https=) |
| MX (1) | MX2021008884A (https=) |
| SG (1) | SG11202107849RA (https=) |
| TW (2) | TWI909513B (https=) |
| WO (1) | WO2020151756A1 (https=) |
| ZA (1) | ZA202104032B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111484490B (zh) * | 2019-01-25 | 2024-07-09 | 百济神州有限公司 | 适合大规模生产b-raf激酶二聚体抑制剂的方法 |
| TWI909513B (zh) | 2019-01-25 | 2025-12-21 | 英屬開曼群島商百濟神州有限公司 | 作為ｂ-ｒａｆ激酶二聚體抑制劑之化合物及其製備方法 |
| WO2022146022A1 (ko) * | 2020-12-29 | 2022-07-07 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도 |
| KR102889693B1 (ko) | 2021-09-08 | 2025-11-20 | 주식회사 엘지에너지솔루션 | 배터리 진단 장치, 배터리 관리 시스템, 배터리 팩, 전기 차량 및 배터리 진단 방법 |
| CN114366717B (zh) * | 2022-01-11 | 2023-06-09 | 四川农业大学 | 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用 |
| WO2023240178A1 (en) * | 2022-06-08 | 2023-12-14 | Mapkure, Llc | Methods of treating cancer with a b-raf inhibitor |
| KR20250069903A (ko) * | 2022-09-26 | 2025-05-20 | 맵큐어, 엘엘씨 | 암 치료를 위한 B-Raf 저해제와 항-EGFR 항체의 조합물 |
| JP2026507361A (ja) * | 2023-03-10 | 2026-03-02 | エスティー ファーム カンパニー リミテッド | 新規固体分散体およびその製造方法 |
| TW202515875A (zh) | 2023-10-12 | 2025-04-16 | 瑞士商百濟神州瑞士有限責任公司 | 包含b-raf激酶二聚體抑制劑之固體形式、其製備方法及用途 |
| WO2025252204A1 (en) * | 2024-06-07 | 2025-12-11 | Beigene (Suzhou) Co., Ltd. | Amorphous solid dispersions of a braf inhibitor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012522791A (ja) | 2009-04-03 | 2012-09-27 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| JP2016505029A (ja) | 2013-01-22 | 2016-02-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 改良されたバイオアベイラビリティを有する薬学的組成物 |
| JP2016523269A (ja) | 2013-06-28 | 2016-08-08 | ベイジーン リミテッド | Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| ES2306646T3 (es) | 1999-02-09 | 2008-11-16 | Pfizer Products Inc. | Composiciones de farmacos basicos con biodisponibilidad incrementada. |
| SE0100733D0 (sv) | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| EP1534276B1 (en) | 2002-09-05 | 2008-11-05 | Medivir AB | Non-nucleoside reverse transcriptase inhibitors |
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| US7618964B2 (en) | 2004-12-23 | 2009-11-17 | Hoffmann-La Roche Inc. | Benzamide derivatives, their manufacture and use as pharmaceutical agents |
| CN101365682A (zh) | 2005-12-08 | 2009-02-11 | 千禧药品公司 | 具有激酶抑制活性的双环化合物 |
| ATE552245T1 (de) | 2006-05-15 | 2012-04-15 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
| JP2010502660A (ja) | 2006-09-06 | 2010-01-28 | エフ．ホフマン−ラ ロシュ アーゲー | プロテインキナーゼインヒビターとしてのヘテロアリール誘導体 |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| CN101702878B (zh) | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| SI2947072T1 (sl) * | 2008-03-17 | 2017-03-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| US20120157453A1 (en) * | 2009-08-28 | 2012-06-21 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2011092088A1 (en) | 2010-01-27 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| WO2011115069A1 (ja) | 2010-03-19 | 2011-09-22 | 第一三共株式会社 | 結晶の網羅的探索 |
| KR101911972B1 (ko) * | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| US9273046B2 (en) | 2011-12-31 | 2016-03-01 | Beigene, Ltd. | Fused tricyclic compounds as Raf kinase inhibitors |
| TR201904980T4 (tr) * | 2012-08-07 | 2019-05-21 | Novartis Ag | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. |
| JP2014189462A (ja) | 2013-03-27 | 2014-10-06 | Osaka Univ | 結晶製造方法、準安定形結晶、医薬の製造方法および医薬 |
| US9670231B2 (en) * | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| TWI909513B (zh) | 2019-01-25 | 2025-12-21 | 英屬開曼群島商百濟神州有限公司 | 作為ｂ-ｒａｆ激酶二聚體抑制劑之化合物及其製備方法 |
-
2020
- 2020-01-22 TW TW113123511A patent/TWI909513B/zh active
- 2020-01-22 TW TW109102401A patent/TWI849043B/zh active
- 2020-01-23 SG SG11202107849RA patent/SG11202107849RA/en unknown
- 2020-01-23 MX MX2021008884A patent/MX2021008884A/es unknown
- 2020-01-23 JP JP2021542104A patent/JP7591504B2/ja active Active
- 2020-01-23 EP EP20744694.9A patent/EP3914591A4/en active Pending
- 2020-01-23 US US17/423,600 patent/US12582604B2/en active Active
- 2020-01-23 KR KR1020217026908A patent/KR20210120039A/ko active Pending
- 2020-01-23 WO PCT/CN2020/073944 patent/WO2020151756A1/en not_active Ceased
- 2020-01-23 CN CN202080010548.8A patent/CN113330011A/zh active Pending
- 2020-01-23 CA CA3123476A patent/CA3123476A1/en active Pending
- 2020-01-23 AU AU2020211000A patent/AU2020211000B2/en active Active
- 2020-01-23 BR BR112021014563-0A patent/BR112021014563A2/pt unknown
-
2021
- 2021-06-11 ZA ZA2021/04032A patent/ZA202104032B/en unknown
- 2021-07-06 IL IL284636A patent/IL284636A/en unknown
-
2024
- 2024-11-18 JP JP2024200421A patent/JP2025017374A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012522791A (ja) | 2009-04-03 | 2012-09-27 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| JP2016505029A (ja) | 2013-01-22 | 2016-02-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 改良されたバイオアベイラビリティを有する薬学的組成物 |
| JP2016523269A (ja) | 2013-06-28 | 2016-08-08 | ベイジーン リミテッド | Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12582604B2 (en) | 2026-03-24 |
| BR112021014563A2 (pt) | 2021-10-05 |
| ZA202104032B (en) | 2022-08-31 |
| EP3914591A1 (en) | 2021-12-01 |
| IL284636A (en) | 2021-08-31 |
| SG11202107849RA (en) | 2021-08-30 |
| CA3123476A1 (en) | 2020-07-30 |
| EP3914591A4 (en) | 2022-11-09 |
| TWI849043B (zh) | 2024-07-21 |
| CN113330011A (zh) | 2021-08-31 |
| WO2020151756A1 (en) | 2020-07-30 |
| MX2021008884A (es) | 2021-08-19 |
| US20220105033A1 (en) | 2022-04-07 |
| TWI909513B (zh) | 2025-12-21 |
| TW202444718A (zh) | 2024-11-16 |
| KR20210120039A (ko) | 2021-10-06 |
| AU2020211000A1 (en) | 2021-08-12 |
| JP2025017374A (ja) | 2025-02-05 |
| TW202043225A (zh) | 2020-12-01 |
| JP2022517675A (ja) | 2022-03-09 |
| AU2020211000B2 (en) | 2025-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7591504B2 (ja) | Ｂ－ｒａｆキナーゼ二量体阻害剤の安定な固体分散体、その調製方法及び使用 | |
| JP6974534B2 (ja) | 縮合複素芳香族ピロリジノンの固体状態形態 | |
| US8592442B2 (en) | Nilotinib HCl crystalline forms | |
| CN104870427B (zh) | Mek抑制剂的制备和包含mek抑制剂的制剂 | |
| WO2020053660A1 (en) | Solid forms of a bet inhibitor | |
| CN112789087B (zh) | Pad酶的苯并咪唑抑制剂 | |
| TW202019415A (zh) | Pad酶之吲哚及氮雜吲哚抑制劑 | |
| WO2016070697A1 (zh) | 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法 | |
| WO2019026014A1 (en) | METHODS FOR PREPARING LIFITEGRAST AND ITS INTERMEDIATES | |
| HRP20020521A2 (en) | Novel processes for making - and a new crystalline form of - leflunomide | |
| TWI836379B (zh) | 化合物的多晶型及其製備方法和應用 | |
| JP5642766B2 (ja) | アデフォビルジピボキシルの新規結晶形及びその製造方法 | |
| IL291855B1 (en) | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[5,4-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran -2-yl]propyl]acetate | |
| KR102847760B1 (ko) | 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도 | |
| CN111484489B (zh) | 无定形的b-raf激酶二聚体抑制剂 | |
| HK40055004A (en) | Stable solid dispersions of b-raf kinase dimer inhibitor, methods of preparation, and uses therefor | |
| EA052614B1 (ru) | Стабильные твердые дисперсии ингибитора димера киназы b-raf, способы их получения и их применения | |
| WO2000029383A1 (en) | Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide | |
| EA047214B1 (ru) | СТАБИЛЬНЫЕ ТВЕРДЫЕ ДИСПЕРСИИ ИНГИБИТОРА ДИМЕРА КИНАЗЫ B-Raf, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ | |
| WO2019210511A1 (zh) | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 | |
| CA3048771C (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
| CN115724846A (zh) | 异喹啉磺酰衍生物新晶型及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240918 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241022 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241118 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7591504 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |